FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to production of PDGF and VEGF binding proteins and recombinant viral particles encoding fused proteins, and can be used in medicine. PDGF and VEGF-bound fused proteins are used in compositions for effective inhibition of PDGF-path and VEGF-path.
EFFECT: viral particles coding PDGF and VEGF binding fusion proteins are used in an effective therapy of corneal neovascularisation.
14 cl, 8 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES WHICH BIND LIGANDS AND USE THEREOF | 2014 |
|
RU2699007C2 |
| ANTIANGIOGENIC INDUCER FUSION PROTEIN AND USING IT | 2012 |
|
RU2560589C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
| FGF-R-Fc FUSED PROTEIN AND USE THEREOF | 2012 |
|
RU2560573C2 |
| COMPOSITIONS AND METHODS OF TREATING AND PREVENTING MACULAR DEGENERATION | 2015 |
|
RU2703145C2 |
| COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
| HYBRID PROTEINS BASED ON HUMAN Notch3 AS TRAPS-INHIBITORS OF Notch3 SIGNAL TRANSMISSION | 2009 |
|
RU2567662C2 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
| ANTAGONISTS OF ALK1 RECEPTOR AND LIGANDS AND THEIR APPLICATION | 2007 |
|
RU2559532C2 |
